N/A N=66 Use of Ultrasonic Bone Scalpel in Adolescent Idiopathic Scoliosis
Adolescent Idiopathic Scoliosis · Posterior Spinal Fusion
Primary: Estimated Blood Loss/Level — 35.21; 38.68 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=984 Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry
Ischemic Stroke
Primary: Number of Participants Assessed for Revascularization With mTICI Grades 2b-3 — 724 Participants
Phase 4 N=302 Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Primary: Percentage of Participants on LCZ696 200 mg Bid at Month 6 — 64.6 Percentage of Participants
N/A N=124 Newborn Feeding and Infant Phenotype
Breast Feeding
Primary: Change in Total Adipose Tissue Volume — 0.718; 0.901; 0.775 Litres
Phase 1 N=6 Mass-balance Study of [14C]-APD421 in Healthy Volunteers
Post-operative Nausea and Vomiting
Primary: Mass Balance — 96.4 percent excreted
N/A N=990 Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk
Contraception · Knowledge, Attitudes, Practice
Primary: Change in Contraceptive Knowledge Assessment (CKA) Score — 0.90; 1.6 scores on a scale — p=<0.0001
Phase 1 N=77 A Study of LY3127760 in Healthy Participants
Healthy Volunteers
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 4 N=3,298 Stress Ulcer Prophylaxis in the Intensive Care Unit
Gastrointestinal Bleeding · Stress Ulcers
Primary: Mortality — 510; 499 Participants
N/A N=2,203 ROOBY Trial Follow-up Extension
All Cause Mortality · MACE
Primary: Long-term All Cause Mortality Between On-pump and Off-pump Patients. — 131; 168; 298; 342 Participants
N/A N=1,976 A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Advanced Prostate Cancer · Prostatic Neoplasms
Primary: To Further Quantify the Risk of Cerebrovascular Events Following Sipuleucel-T Therapy for All Subjects — 1.2 events per 100 patient years
N/A N=81,921 Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Psychiatric Hospitalization — 4965; 5247; 2385; 3093 Participants
N/A N=142 Nurse-Led Interprofessional Mental Health Promotion Intervention for Older Home Care Clients
Depressive Symptoms
Primary: Centre for Epidemiological Studies in Depression Scale — -3.52 units on a scale
Phase 4 N=50 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
NeuroEndocrine Tumours
Primary: Assessment of Clinical Symptomatic Response — 77.8; 95.5; 87.5; 22.2 Percentage of Subjects — p==0.126
Phase 1 N=80 Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine
Infections, Meningococcal
Primary: Number of Subjects With Any Solicited Local and Systemic Adverse Events (AEs) — 0; 0; 0; 0 Participants
N/A N=66 Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection
Tuberculosis
Primary: Number of Participants With Concordant CST001 Assay Results for All Replicates Across Three Testing Sites — 32; 23 Participants